We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Overactive Brain Circuit Faulted for Depression

By Biotechdaily staff writers
Posted on 10 Aug 2004
A brain imaging study has found that an emotion-regulating brain circuit is overactive in people who are prone to depression. More...
The finding was reported in the August 2004 issue of Archives of General Psychiatry.

Researchers discovered the abnormality in brains of those whose depressions relapsed when a key brain chemical messenger was experimentally reduced. Even when in remission, most subjects with a history of mood disorder experienced a temporary recurrence of symptoms when their brains were experimentally sapped of tryptophan, the chemical precursor of serotonin, the neurotransmitter boosted by antidepressant medications.

Neither a placebo procedure in patients nor tryptophan depletion in healthy volunteers triggered the mood and brain activity changes. The scans revealed that a key motion-processing circuit was overactive only in patients in remission--whether or not they had re-experienced symptoms--and not in controls. Since the abnormal activity did not reflect mood state, the finding suggests that tryptophan depletion unmasks an inborn trait associated with depression.

The researchers scanned subjects with positron emission tomography (PET) after their blood tryptophan levels were reduced by about three-fourths, using a radioactive tracer that reveals where the brain is active during a particular experimental condition. Pills containing seven essential amino acids or identical-looking placebo pills were given randomly to 27 unmedicated depressed patients in remission and 19 controls. Sixteen patients experienced a transient return of symptoms under tryptophan depletion, but their mood lifted to normal by the next day. Compared to controls, the patients showed increased brain activity in areas involved in regulating emotions.

"Since brain function appears to be disregulated even when patients are in remission, they need to continue long-term treatment beyond the symptomatic phase of their illness,” noted Dr. Alexander Neumeister, one of the authors of the study, conducted by the U.S. National Institute of Mental Health (Bethesda, MD, USA).




Related Links:
NIMH

New
Gold Member
Aspiration System
VACUSAFE
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Clinical Informatics Platform
CLARION™
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.